Q&A: How IQVIA Keeps Pharmacists Engaged with US Prescription Drug Use
Drug Topics
JULY 14, 2025
Currently it’s going to be slowing to upper single digits through the forecast period, basically because 2 of the leading drugs, there's immune checkpoint inhibitors—nivolumab is the molecule—and pembrolizumab is Keytruda, 2 of those are going off patent in 2028 and 2029. That trend is in the low-to-mid teens in terms of growth rate.
Let's personalize your content